NHS Patients Denied Breakthrough Alzheimer’s Drugs
15th June 2025
Breakthrough drugs for Alzheimer’s will be refused for use on the NHS this week, denying the treatments to about 70,000 patients in England.
Lecanemab, made by Eisai, and donanemab, made by Eli Lilly, are the first drugs proven to slow the underlying cause of dementia, clearing toxic amyloid protein from the brain and delaying cognitive decline.
How about that great government-provided health care, eh? Don’t you wish we had a system like that here in the U.S.?
Well, it’s coming….
UPDATE: After 77 years and another £29bn, NHS chiefs fear public losing patience